RESUMO
OBJECTIVE: To preliminarily explore the relationship between thrombosis and its associated factors in patients with coronary heart disease (CHD) of turbidity-phlegm blocking syndrome (TPB), and to study its acting mechanism. METHODS: Plasma levels of thrombosis-associated factors, including Von Willebrand factor: (vWF), D-dimer, and fibrinogen (Fg), in 85 patients of CHD with TPB, 93 with CHD of non-TPD, and 89 healthy persons were detected and compared. RESULTS: Levels of the three factors were increased in all the CHD: patients, and were higher in TPB patients than in non-TPB patients (P<0.01 or P<0.05). CONCLUSION: The TPB: syndrome in CHD patients was closely related to the blood coagulation-fibrinolytic system; they might be in pre-thrombosis state, and the plasma levels of vWF, D-dimer, and Fg could be taken as the objective indices for thrombosis differentiation of TPB syndrome in CHD patients.
Assuntos
Doença das Coronárias/fisiopatologia , Trombose/fisiopatologia , Estudos de Casos e Controles , Doença das Coronárias/sangue , Produtos de Degradação da Fibrina e do Fibrinogênio/metabolismo , Fibrinogênio/análise , Humanos , Trombose/sangue , Fator de von Willebrand/metabolismoRESUMO
OBJECTIVE: To observe Wenxinkeli viral myocarditis clinical efficacy and safety. METHODS: 45 patients were randomly divided into two groups. Treatment group given Wenxinkeli (5 g, 3 times a day with warm water) treatment, the control group given adenosine triphosphate, coenzyme A, vitamin C, coenzyme Q10 and other nutrients cardiac drugs, treatment for 4 weeks. RESULTS: The treatment of clinical symptoms, signs and ECG improvement, restoration of enzyme than the control group, there was a significant difference (P < 0.05). CONCLUSIONS: Wenxinkeli ventricular premature treatment of viral myocarditis is effective, and no significant adverse reactions, safety, good.